E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10020161 |
E.1.2 | Term | HIV infection |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
This program is designed to provide expanded access to MK-0518 prior to the product’s approval and availability on the market. The safety and tolerability of MK-0518 400 mg b.i.d. for the treatment of HIV-1 infection will be monitored. |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
In patients with document HIV-1 infection: 1. Patient is a male or female at least 16 years of age. 2. Patient has limited or no treatment options due to resistance or intolerance to multiple antiretroviral regimens. • Patient has documented resistance to at least 1 drug in each of the 3 classes of licensed oral ARTs (NNRTI, NRTI, and PI) by genotype or phenotype testing. • Intolerance is defined as having had a clinically significant adverse event which in the opinion of the investigator provides a contraindication to the use of any drug in that class. 3. Patient is not achieving adequate virologic suppression on his/her current regimen and at risk of clinical or immunologic progression. 4. Patients should be considered clinically stable, in the opinion of the investigator, at the time of entry into the study; i.e., clinical status and all chronic medications, except for antiretroviral agents, should be unchanged for at least 2 weeks prior to the start of treatment in this study. 5. Patient who is of reproductive potential agrees to use an acceptable method of birth control throughout the study. Acceptable method of birth control is defined as intrauterine device (IUD), diaphragm with spermicide, condoms, or abstinence. OR Patient who is not of reproductive potentia* ; is not sexually active, whose current partner(s) is not of reproductive potential, or whose sexual activity is exclusively homosexual is eligible without requiring the use of contraception. Note: Use of oral or other hormonal contraception is permitted. Because of the potential interactions of hormonal contraceptives with other antiretrovirals in the OBT, another reliable second method of contraception should be used
* A patient who is not of reproductive potential is defined as: one who has reached menopause (no menses for 1 year), undergone hysterectomy, bilateral oophorectomy tubal ligation or a successful vasectomy. A successful vasectomy is defined as: (1) microscopic documentation of azoospermia, or (2) a vasectomy more than 2 years ago with no resultant pregnancy despite sexual activity postvasectomy.
|
|
E.4 | Principal exclusion criteria |
1. Prior or current participation in MK-0518 clinical trial. Note: Patients who have been receiving MK-0518 via other compassionate use/emergency use mechanisms, can be enrolled in this study. 2. Patient requires or is anticipated to require any of the prohibited medications noted in the protocol. 3. Patients with acute hepatitis due to any cause or clinically significant chronic liver disease including but not limited to cirrhosis, ascites, encephalopathy, hypoalbuminemia, prolonged PT/PTT and/or esophageal varices. 4. Patient has severe renal insufficiency defined as a calculated creatinine clearance at time of Screening <30 mL/min, based on the Cockcroft-Gault equation which is as follows (and 0.85X this value for females): Clcr (mL/min) = (140-age) x weight (in kg) ------------------------------------------------------ 72 x serum creatinine (mg/dL) 5. Patient has a condition (including but not limited to alcohol or other substance abuse) which in the opinion of the investigator would interfere with patient compliance or safety. 6. Female patient is pregnant or breast-feeding, or expecting to conceive or donate eggs during the study. Male patient is planning to impregnate or provide sperm donation during the study. Note: All female patients must have a negative pregnancy test at Treatment Day 1. 7. Inability to obtain signed informed consent from a patient age 18 or older, or when a parent/legal representative has provided consent, the inability to obtain assent from a patient 16 or 17 years of age. Note: If local guidelines permit, consent may be obtained from those patients who are 16 or 17 years of age. 8. Patient has significant hypersensitivity or other contraindication to any of the components of the study drug.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
This program is designed to provide expanded access to MK-0518 prior to the product's approval and availability on the market. The primary analyses of safety will be based upon the All Patients As Treated (APaT) approach which includes all patients who received one or more doses of test drug therapy. All patients who take study medication will be included in the analysis of safety and tolerability. Only those adverse experiences that occur while on study therapy or within 14 days after discontinuation of study therapy will be included in the analysis. For assessment of safety and tolerability, counts and percentages of patients with clinical or laboratory adverse experiences of the following type will be tabulated (1) serious adverse experience, (2) drug-related adverse experiences that result in grade 3 or above laboratory toxicity; (3) drug related adverse experiences that lead to treatment interruption; (4) drug related adverse experiences leading to discontinuation. No formal hypothesis testing will be done.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
To provide early access to MK-0518 |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 15 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 100 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The investigator will follow the patients according to the standard of care. The study will continue until approximately 3 months after product launch. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |